Session » Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2858

A Phosphodiesterase 4 Inhibitor for Psoriatic Arthritis: Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2845

A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2875

Anti-TNF Therapy Is Not Associated with an Increase in Neoplasias in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry

9:00AM-11:00AM: Abstract Number: 2851

Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry

9:00AM-11:00AM: Abstract Number: 2849

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2888

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2889

Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis

9:00AM-11:00AM: Abstract Number: 2891

Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2876

Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2882

Baseline Extent of Damage at the Spine Predicts Radiographic Progression in Korean Patients Using Golimumab for Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2841

Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry

9:00AM-11:00AM: Abstract Number: 2860

Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 2863

Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2839

Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension

9:00AM-11:00AM: Abstract Number: 2836

Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2859

Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2871

Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period

9:00AM-11:00AM: Abstract Number: 2866

Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period

9:00AM-11:00AM: Abstract Number: 2856

Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylarthritis As Well As Peripheral Arthritis: Results from 2 Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

9:00AM-11:00AM: Abstract Number: 2884

Epidemiological Parameters Affecting Therapeutic Response in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2850

Etanercept Treatment in Psoriatic Arthritis: Need for Co-Medication?

9:00AM-11:00AM: Abstract Number: 2838

Evidence of Serological IL-23/IL-17 Axis Activation in Ankylosing Spondylitis Patients with Long-Term TNF Blockade: The Missing Therapy Target?

9:00AM-11:00AM: Abstract Number: 2869

Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2867

Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study

9:00AM-11:00AM: Abstract Number: 2881

Infliximab in Spondyloarthritis Patients: Utility of Drug Level Monitoring

9:00AM-11:00AM: Abstract Number: 2895

Intraarticular Sacroiliac Corticosteroid Injections in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2862

Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2840

Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2843

Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)

9:00AM-11:00AM: Abstract Number: 2885

Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study

9:00AM-11:00AM: Abstract Number: 2835

Long-Term Improvements with Certolizumab Pegol in Joints and Extra-Articular Manifestations of Psoriatic Arthritis in Patients with and without Prior Anti-TNF Exposure

9:00AM-11:00AM: Abstract Number: 2854

Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study

9:00AM-11:00AM: Abstract Number: 2864

Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 2865

Methotrexate and Leflunomide Survival in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2846

Modifications to Biologic Therapy and Economic Implications in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2848

Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2855

Non-Response to Antitnf Treatment in Psoriatic Arthritis Can be Predicted By an Objective Automated Measurement of Fluorescence-Signal Intensities in Fluorescence-Optical Imaging Technique – the First Interims Analysis of the Xplore-Study

9:00AM-11:00AM: Abstract Number: 2873

Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA

9:00AM-11:00AM: Abstract Number: 2870

Predictors of Early Minimal Disease Activity in Psa Patients Treated with Anti-TNF in a Real-World Registry

9:00AM-11:00AM: Abstract Number: 2847

Predictors of Therapeutic Response in Ankylosing Spondylitis Patients Initiating Therapy with Adalimumab in a German Non-Interventional Study

9:00AM-11:00AM: Abstract Number: 2893

Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment

9:00AM-11:00AM: Abstract Number: 2880

Real-World Impact of Anti-TNF Medication Use on Patient Reported Outcomes in a Prospective Cohort of Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2883

Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab

9:00AM-11:00AM: Abstract Number: 2868

Relative Efficacy of Adalimumab Versus Secukinumab in Active Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison

9:00AM-11:00AM: Abstract Number: 2887

Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 2853

Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial

9:00AM-11:00AM: Abstract Number: 2890

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naïve Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 2896

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

9:00AM-11:00AM: Abstract Number: 2844

Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 2886

Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis

9:00AM-11:00AM: Abstract Number: 2892

Statin Treatment in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2837

Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2857

The 8-Year Retention Rate of the First TNF-Inhibitor in the Treatment of Spondyloarthropathies: Real-Life Data from Three Local Registries

9:00AM-11:00AM: Abstract Number: 2894

The Majority of Patients with Moderate to Severe Psoriatic Arthritis Had Existing Structural Damage, Predisposing Them to Further Progression, Which Was Markedly Inhibited By Adalimumab

9:00AM-11:00AM: Abstract Number: 2878

Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents

9:00AM-11:00AM: Abstract Number: 2861

Treatment Patterns of Subcutaneous Biologic Agent Use Among Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2842

Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome

9:00AM-11:00AM: Abstract Number: 2872

Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2874

Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings

9:00AM-11:00AM: Abstract Number: 2879

What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?

9:00AM-11:00AM: Abstract Number: 2877

What Is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].